Generative AI-Assisted Discovery of HPK1 Inhibitors.
An early application of REINVENT, AstraZeneca's in-house generative molecular design platform, is described to identify new inhibitor scaffolds for hematopoietic progenitor kinase 1 (HPK1), demonstrating the value of integrating generative AI with medicinal chemistry expertise.